SUHA FAISAL OMAR ABU KHALAF MD
Prescription History 1235623331
Internal Medicine - Infectious Disease in Fargo, ND

NPI Status: Active since June 21, 2018

Contact Information

3000 32ND AVE S
FARGO, ND
ZIP 58103
Phone: (701) 364-8900

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SUHA FAISAL OMAR ABU KHALAF MD, an active Infectious Disease specialist practicing in Fargo, ND. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 227 documented patient claims. Among these therapy options, the most frequently utilized medication is Biktarvy, which accounts for 94 claims alone.

Medication Index

No matching medications currently found on file.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 24.0
Days Supply 646
ND State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills29.2
Peer Average Days Supply298
Conservative Utilization

This provider writes prescriptions for this formulation 40.7% less frequently than the standard regional baseline metric for practitioners inside ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $232.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.53

State Avg Cost Per Claim

$9.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 94
30-Day Fills 94.0
Days Supply 2,820
ND State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills27.3
Peer Average Days Supply814
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 248.1% higher than the standard regional baseline profile for ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $386,292.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,109.49

State Avg Cost Per Claim

$3,872.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Cefadroxil

Generic Formulation: CefadroxilSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 17.0
Days Supply 430
ND State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills31.1
Peer Average Days Supply699
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.2% less volume than the regional standard for practitioners inside ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $367.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.39

State Avg Cost Per Claim

$25.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. It belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Cefazolin Sodium

Generic Formulation: Cefazolin SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 170
ND State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.8
Peer Average Days Supply159
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,138.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$85.54

State Avg Cost Per Claim

$53.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

Therapeutic Applications

Cefazolin is an antibiotic used to treat a wide variety of bacterial infections. It may also be used before and during certain surgeries to help prevent infection. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria.

Dovato

Generic Formulation: Dolutegravir Sodium/LamivudineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 52
30-Day Fills 52.0
Days Supply 1,560
ND State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills15.3
Peer Average Days Supply460
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 246.7% higher than the standard regional baseline profile for ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $158,649.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,050.95

State Avg Cost Per Claim

$2,829.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains 2 drugs: dolutegravir and lamivudine. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Lamivudine belongs to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Dolutegravir belongs to a class of drugs known as integrase inhibitors. This medication is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Ethambutol Hcl

Generic Formulation: Ethambutol HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 21.0
Days Supply 608
ND State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills27.4
Peer Average Days Supply797
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,651.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$110.09

State Avg Cost Per Claim

$47.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)

Therapeutic Applications

Ethambutol is used with other medications to treat tuberculosis (TB). Ethambutol is an antibiotic and works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Juluca

Generic Formulation: Dolutegravir/RilpivirineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 420
ND State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.0
Peer Average Days Supply510
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $50,433.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,602.41

State Avg Cost Per Claim

$3,291.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dolutegravir/rilpivirine is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Dolutegravir is an integrase inhibitor while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Both drugs block the virus from growing and infecting more cells. Dolutegravir/rilpivirine is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SUHA FAISAL OMAR ABU KHALAF MD provides transparency into local medical care patterns within Fargo, ND.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.